These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8292731)

  • 1. Experimental hypothyroidism increases plasminogen activator inhibitor activity in rat plasma.
    Padró T; van den Hoogen CM; Emeis JJ
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):797-800. PubMed ID: 8292731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of thyroxine on plasminogen activator and inhibitor activity in rat.
    Bubber P; Bubber N; Bansal DD
    Indian J Exp Biol; 2009 Feb; 47(2):147-50. PubMed ID: 19374171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism.
    Chadarevian R; Bruckert E; Leenhardt L; Giral P; Ankri A; Turpin G
    J Clin Endocrinol Metab; 2001 Feb; 86(2):732-7. PubMed ID: 11158038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of octreotide on epidermal growth factor receptor, tissue plasminogen activator, and plasminogen activator inhibitor during intraperitoneal adhesion formation.
    Lai HS; Chen Y; Chang KJ; Chen WJ
    J Gastroenterol; 2003; 38(6):555-60. PubMed ID: 12825131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of growth hormone on fibrinolytic system in rat.
    Bubber P; Singh KP; Arora S; Bansal DD
    Indian J Exp Biol; 1998 May; 36(5):514-6. PubMed ID: 9717468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in plasma homocysteine levels of rats with experimentally induced hypothyroidism and hyperthyroidism.
    Ozkan Y; Dönder E; Güney H; Baydaş G
    Neuro Endocrinol Lett; 2005 Oct; 26(5):536-40. PubMed ID: 16264404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
    Paloma MJ; Páramo JA; Rocha E
    Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of different treatments on plasma t-PA and PAI activity in AMI].
    Zhu G
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Oct; 15(5):374-9. PubMed ID: 8168223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
    Buduneli N; Buduneli E; Ciotanar S; Atilla G; Lappin D; Kinane D
    J Clin Periodontol; 2004 Jul; 31(7):556-61. PubMed ID: 15191592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells.
    Kuiper J; Otter M; Voorschuur AH; van Zonneveld AJ; Rijken DC; van Berkel TJ
    Thromb Haemost; 1995 Nov; 74(5):1298-304. PubMed ID: 8607113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly cirrhotic rat liver.
    Seki T; Imai H; Uno S; Ariga T; Gelehrter TD
    Thromb Haemost; 1996 May; 75(5):801-7. PubMed ID: 8725727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ; Boon GI; Jansen JW; Bouma BN
    Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
    Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of thyroxine on fibrinolytic system in rat.
    Bubber P; Chauhan A; Sharma A; Bubber N; Bansal DD
    Indian J Physiol Pharmacol; 2012; 56(3):267-72. PubMed ID: 23734442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.